image: Researchers have exploited the CRISPR/Cas9 gene editing technique to correct the disease causing mutation in hematopoietic stem cells from patients with sickle cell disease, successfully engrafting these cells in mice. This material relates to a paper that appeared in the Oct. 12, 2016, issue of Science Translational Medicine, published by AAAS. The paper, by M.A. DeWitt at University of California - Berkeley in Berkeley, CA, and colleagues was titled, "Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells." view more
Credit: Val Altounian /<i>Science Translational Medicine</i> (2016)